[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 22, 1997

The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)-Reply

Author Affiliations

Bowman Gray School of Medicine Winston-Salem, NC
University of Nevada, Reno
Heart Research Institute Miami, Fla
Preventive Cardiology Inc Augusta, Ga
University of California at Davis
Scientific Application Co Inc Birmingham, Ala
Wayne State University Detroit, Mich

JAMA. 1997;277(4):297-298. doi:10.1001/jama.1997.03540280035026
Abstract

In Reply.  —Regarding the comments by Dr Kaufman on the ultrasound data, the ultrasound instrument used in MIDAS was Biosound 2000 II spectrum analysis with 8-MHz annular arrays (approximate axial resolution, 0.3 mm). This was defined in the original protocol and previously published.1 Kaufman notes that the intimal-medial thickness differences in MIDAS are less than the axial resolution of ultrasound equipment, and therefore the analyses may overstate the ability of these instruments to determine the fine differences reported. The differences presented were calculated, not measured, by comparing within-group or between-group intimal-medial thickness data. That it is not possible to directly measure these differences does not affect the validity or appropriateness of determining their presence or use in analyses of grouped data.The comments by Dr Abt concerning the statistical significance (or lack thereof) of the difference in cardiovascular events between patients treated with hydrochlorothiazide and isradipine in the MIDAS trial seem

×